18-MC reduces methamphetamine and nicotine self-administration in rats

Area of Science:

• Neuroscience
• Pharmacology
• Addiction Research

Background:

• 18-methoxycoronaridine (18-MC), an iboga alkaloid congener, has previously shown efficacy in reducing morphine and cocaine self-administration in rats.
• Understanding the broader effects of 18-MC on different substance use disorders is crucial for developing novel addiction treatments.

Purpose of the Study:

• To investigate the dose-dependent effects of 18-methoxycoronaridine (18-MC) on the intravenous self-administration of methamphetamine and nicotine in a rat model.
• To compare the efficacy of 18-MC across multiple drugs of abuse, including morphine, cocaine, methamphetamine, and nicotine.

Main Methods:

• Rats were administered varying doses of 18-methoxycoronaridine (18-MC) via intraperitoneal injection (1-40 mg/kg).
• Intravenous self-administration of methamphetamine and nicotine was monitored to assess the drug's effects.
• The duration of 18-MC's effect on drug self-administration was evaluated.

Main Results:

• 18-methoxycoronaridine (18-MC) significantly decreased methamphetamine and nicotine self-administration in a dose-dependent manner.
• The reduction in drug self-administration persisted for at least 24 hours following the highest dose of 18-MC.
• 18-MC demonstrated the least efficacy against methamphetamine self-administration and the highest potency against nicotine self-administration among the studied drugs.

Conclusions:

• 18-methoxycoronaridine (18-MC) exhibits broad-spectrum anti-addictive potential, effectively reducing the self-administration of multiple drugs of abuse.
• The findings suggest that 18-MC's anti-addictive properties may be partly mediated by its action as a nicotinic antagonist.
• Further research into 18-MC's mechanisms of action could lead to new therapeutic strategies for substance use disorders.